Skip to Content
Looking to save on your medications?  Find out how 

3 Interactions found for:

tadalafil
Interactions Summary
  • 2 Major
  • 1 Moderate
  • 0 Minor
  • tadalafil

Drug Interactions

A total of 351 medications are known to interact with tadalafil. Add another medication to view potential interactions with this medication.

Drug and Food Interactions

Moderate
Tadalafil + Food

The following applies to the ingredients: Tadalafil

GENERALLY AVOID: Coadministration with grapefruit juice is likely to increase the plasma concentrations of tadalafil, which is primarily metabolized by CYP450 3A4. However, the interaction has not been studied. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.

MONITOR: Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors such as tadalafil are used with alcohol, as both are mild systemic vasodilators. In clinical pharmacology studies, more subjects administered alcohol at a dose of 0.7 g/kg (equivalent to approximately 6 ounces of 80-proof vodka in an 80-kg male; consumed within 10 minutes in study subjects, providing blood alcohol levels of 0.08%) in combination with tadalafil 10 or 20 mg single doses had clinically significant decreases in blood pressure than with alcohol alone. There were reports of postural dizziness, and orthostatic hypotension was observed in some. When tadalafil 20 mg was administered with alcohol at a lower dose of 0.6 g/kg (equivalent to approximately 4 ounces of 80-proof vodka in an 80-kg male), orthostatic hypotension was not observed, dizziness occurred with similar frequency relative to alcohol alone, and the hypotensive effects of alcohol were not potentiated. Neither tadalafil nor alcohol affected the plasma concentrations of the other.

MANAGEMENT: Caution is recommended with concurrent consumption of large amounts of alcohol in patients taking tadalafil as it may increase the potential for orthostatic signs and symptoms, such as increase in heart rate, decrease in standing blood pressure, dizziness, and headache. It may also be appropriate to avoid consuming large amounts of grapefruit juice.

References

  1. "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation (2009):
  2. "Product Information. Opsynvi (macitentan-tadalafil)." Actelion Pharmaceuticals US Inc (2024):
  3. "Product Information. Adcirca (tadalafil)." Eli Lilly and Company Ltd (2023):
  4. "Product Information. Opsynvi 10/40 (macitentan-tadalafil)." Janssen-Cilag Pty Ltd (2024):
  5. "Product Information. Opsynvi (macitentan-tadalafil)." Janssen Inc (2025):
  6. "Product Information. Tadalafil (tadalafil)." Amneal Pharmaceuticals LLC (2019):
  7. "Product Information. Ach-Tadalafil (tadalafil)." Accord Healthcare Inc (2021):
  8. "Product Information. Cialis (tadalafil)." Eli Lilly Australia Pty Ltd (2024):

Drug and Pregnancy Interactions

The following applies to the ingredients: Tadalafil

Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia (BPH): This drug is not indicated for use in women for such indications.
Pulmonary Arterial Hypertension (PAH): This drug should be used only if clearly needed.
-According to some authorities: Use should be avoided.

AU TGA pregnancy category: B1
US FDA pregnancy category (PAH): B
US FDA pregnancy category (ED and BPH): Not assigned.

US FDA Risk Summary (ED and BPH): No data available on use of this drug in pregnant women to inform a drug-related risk.

Animal studies have failed to reveal evidence of teratogenicity, embryotoxicity, or fetotoxicity when given to pregnant rats or mice during organogenesis, at exposure up to 11 times maximum the recommended human dose (MRHD) of 20 mg/day. In a perinatal/postnatal developmental study in rats, postnatal pup survival decreased following maternal exposure to unbound tadalafil concentrations greater than 5 times the MRHD. Signs of maternal toxicity occurred at doses greater than 8 times the MRHD. Surviving offspring had normal development and reproductive performance. There are no controlled data in human pregnancy.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

References

  1. "Product Information. Cialis (tadalafil)." Lilly, Eli and Company (2003):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation (2009):

Drug and Breastfeeding Interactions

The following applies to the ingredients: Tadalafil

This drug is not indicated for use in women

Adcirca (R):
UK: Use should be avoided.
AU and US: Caution is recommended.

Excreted into human milk: Data not available
Excreted into animal milk: Yes

Comments: The effects in the nursing infant are unknown.

This drug and/or its metabolites were excreted in the milk of lactating rats at concentrations up to 2.4-fold higher than the maximal maternal plasma concentration. A risk to the breastfed child cannot be excluded. There are no human data on the excretion of this drug into breast milk.

References

  1. "Product Information. Cialis (tadalafil)." Lilly, Eli and Company (2003):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation (2009):

Therapeutic Duplication Warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Switch to: Consumer Interactions

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Disclaimer: This content should not be considered complete and should not be used in place of a call or visit to a healthcare professional. Use of this content is subject to our terms of use & medical disclaimer.